Natalizumab for the treatment of relapsing multiple sclerosis

Por Rudick, Richard A, Panzara, Michael A
Publicado em 2008

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA

Por Radue, Ernst-Wilhelm, Sprenger, Till, Gaetano, Laura, Mueller-Lenke, Nicole, Cavalier, Steve, Thangavelu, Karthinathan, Panzara, Michael A., Donaldson, Jessica E., Woodward, Fiona M., Wuerfel, Jens, Wolinsky, Jerry S., Kappos, Ludwig
Publicado no Neurol Neuroimmunol Neuroinflamm (2017)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Por Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Publicado no Neurology (2016)

Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease

Por Claassen, Daniel O., Corey-Bloom, Jody, Dorsey, E. Ray, Edmondson, Mary, Kostyk, Sandra K., LeDoux, Mark S., Reilmann, Ralf, Rosas, H. Diana, Walker, Francis, Wheelock, Vicki, Svrzikapa, Nenad, Longo, Kenneth A., Goyal, Jaya, Hung, Serena, Panzara, Michael A.
Publicado no Neurol Genet (2020)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

Por Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Publicado no Neurology (2016)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Por Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Publicado no Neurology (2017)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Por Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Publicado no Neurology (2017)

New Directions in Clinical Trials for Frontotemporal Lobar Degeneration: Methods and Outcome Measures

Por Boxer, Adam L., Gold, Michael, Feldman, Howard, Boeve, Bradley F., Dickinson, Susan L.-J., Fillit, Howard, Ho, Carole, Paul, Robert, Pearlman, Rodney, Sutherland, Margaret, Verma, Ajay, Arneric, Stephen P., Alexander, Brian M., Dickerson, Bradford C., Dorsey, Earl Ray, Grossman, Murray, Huey, Edward D., Irizarry, Michael C., Marks, William J., Masellis, Mario, McFarland, Frances, Niehoff, Debra, Onyike, Chiadi U., Paganoni, Sabrina, Panzara, Michael A., Rockwood, Kenneth, Rohrer, Jonathan D., Rosen, Howard, Schuck, Robert N., Soares, Holly D., Tatton, Nadine
Publicado no Alzheimers Dement (2020)